{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:39:12Z","timestamp":1783021152233,"version":"3.54.6"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Emerging Omicron sublineages XBB.1.16 and EG.5.1.1 have caused breakthrough infections, challenging vaccine efficacy. Hybrid immunity\u2014vaccination plus prior SARS-CoV-2 infection\u2014augments neutralizing activity. We investigated whether innate immune responses also contribute to breakthrough prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed samples from a previous case-control study of 50 breakthrough infection cases and 50 controls, all adults with \u22653 mRNA vaccine doses, recruited in June 2023 during the XBB.1.5 wave in Japan. Participants were classified as hybrid immunity (prior PCR-confirmed infection or N-IgG positive), high-vaccine-induced immunity (N-IgG negative, S-IgG &amp;gt; 10\n                      <jats:sup>4<\/jats:sup>\n                      U\/mL), or low-vaccine-induced immunity (N-IgG negative, S-IgG &amp;lt; 10\n                      <jats:sup>4<\/jats:sup>\n                      U\/mL). Neutralization titers (NT\n                      <jats:sub>50<\/jats:sub>\n                      ) were measured against ancestral SARS-CoV-2, XBB.1.16, and EG.5.1.1. Cytokines and innate markers were analyzed in serum and cell-based assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Breakthrough cases were enriched in the low-vaccine-induced immunity group, with fewer exhibiting hybrid immunity. Hybrid immunity yielded higher NT\n                      <jats:sub>50<\/jats:sub>\n                      values than vaccine-only groups, but humoral immunity alone did not predict breakthrough infection. Cytokine analysis showed elevated IL-8 in hybrid non-breakthrough participants, with no differences in SARS-CoV-2-specific T-cell responses. Macrophages stimulated with the nucleocapsid protein induced IL-8, which promoted neutrophil chemotaxis. S100A8\/A9, a neutrophil activation marker, correlated with IL-8 and was elevated in hybrid immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Hybrid immunity may protect against Omicron XBB.1.16\/EG.5.1.1 via IL-8\u2013dependent macrophage\u2013neutrophil interactions, highlighting a synergistic role of humoral and innate immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1807238","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:30:19Z","timestamp":1783017019000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan"],"prefix":"10.3389","volume":"17","author":[{"given":"Kouki","family":"Matsuda","sequence":"first","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, Center for Clinical Sciences, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Motozono","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University","place":["Kumamoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Aritsu","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University","place":["Kumamoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Noborio","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takada","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiyori","family":"Sasagawa","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Akahori","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoto","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University","place":["Kumamoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mizoue","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, Center for Clinical Sciences, Japan Institute for Health Security","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00278-5","article-title":"Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant","volume":"23","author":"Yamasoba","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00553-4","article-title":"Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5","volume":"23","author":"Kaku","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/vaccines12091051","article-title":"Hybrid immunity against SARS-CoV-2 variants: a narrative review of the literature","volume":"12","author":"Tsagkli","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01123-x","article-title":"BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality","volume":"7","author":"Jung","year":"2022","journal-title":"Nat Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae519","article-title":"Protection of omicron bivalent vaccine, previous infection, and their induced neutralizing antibodies against symptomatic infection with omicron XBB.1.16 and EG.5.1","volume":"11","author":"Yamamoto","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad317","article-title":"Preinfection neutralizing antibodies, Omicron BA.5 breakthrough infection, and Long COVID: a propensity score-matched analysis","volume":"228","author":"Yamamoto","year":"2023","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1038\/s41598-021-84733-5","article-title":"Neutralization of SARS-coV-2 with igg from COVID-19-convalescent plasma","volume":"11","author":"Maeda","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vaccines9010054","article-title":"Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophages-potential implications for cytokine storm syndrome","volume":"9","author":"Karwaciak","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.ra118.005798","article-title":"Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal","volume":"294","author":"Matsuda","year":"2019","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110118","article-title":"Dysregulated metabolism underpins Zika-virus-infection-associated impairment in fetal development","volume":"37","author":"Yau","year":"2021","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/bioengineering9010021","article-title":"Impact of electrospun piezoelectric core-shell PVDFhfp\/PDMS mesh on tenogenic and inflammatory gene expression in human adipose-derived stem cells: comparison of static cultivation with uniaxial cyclic tensile stretching","volume":"9","author":"Baumgartner","year":"2022","journal-title":"Bioeng (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/gan032","article-title":"CXCL10 and IL-6 induce chemotaxis in human trophoblast cell lines","volume":"14","author":"Dominguez","year":"2008","journal-title":"Mol Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100122","article-title":"A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro","volume":"1","author":"Matsuda","year":"2021","journal-title":"Cell Rep Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.1894","article-title":"Store-operated Ca(2)(+) entry mediated regulation of polarization in differentiated human neutrophil-like HL-60 cells under hypoxia","volume":"9","author":"Ma","year":"2014","journal-title":"Mol Med Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2019-00004","article-title":"Kras promotes myeloid differentiation through Wnt\/beta-catenin signaling","volume":"1","author":"Yokoyama","year":"2019","journal-title":"FASEB Bioadv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2287118","article-title":"The characterization of CD8(+) T-cell responses in COVID-19","volume":"13","author":"Yang","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8108","DOI":"10.1038\/s41598-022-12252-y","article-title":"Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein","volume":"12","author":"Nakayama","year":"2022","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2021.100996","article-title":"Neutrophils at the crossroads of acute viral infections and severity","volume":"81","author":"Rawat","year":"2021","journal-title":"Mol Aspects Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.500","article-title":"Role of neutrophils in acute viral infection","volume":"9","author":"Ma","year":"2021","journal-title":"Immun Inflammation Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2139\/ssrn.3611903","article-title":"Excessive neutrophils and neutrophil extracellular traps in COVID-19","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad526","article-title":"Neutrophil virucidal activity against SARS-CoV-2 is mediated by neutrophil extracellular traps","volume":"229","author":"Dos Ramos Almeida","year":"2024","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101583","DOI":"10.2139\/ssrn.4677490","article-title":"SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire","volume":"5","author":"Tarke","year":"2024","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01298","article-title":"S100A8\/A9 in inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300640","article-title":"S100A9: the unusual suspect connecting viral infection and inflammation","volume":"212","author":"Boucher","year":"2024","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2101058","article-title":"Innate immune memory and the host response to infection","volume":"208","author":"Sherwood","year":"2022","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.chom.2023.05.004","article-title":"The role of trained immunity in COVID-19: lessons for the next pandemic","volume":"31","author":"Netea","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1011936","article-title":"A review of cytokine-based pathophysiology of Long COVID symptoms","volume":"10","author":"Low","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102228","article-title":"Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infectionimmunity and inflammaion in post-acute sequelae of SARS-CoV-2 infection","volume":"77","author":"Newell","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13320","article-title":"Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease","volume":"163","author":"Patel","year":"2021","journal-title":"Immunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051175","article-title":"Physiological and pathological inflammation induced by antibodies and pentraxins","volume":"10","author":"Geyer","year":"2021","journal-title":"Cells"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:30:20Z","timestamp":1783017020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1807238"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807238","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1807238"}}